Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-16T12:31:20.486Z Has data issue: false hasContentIssue false

Knowledge Diversity in the Emerging Global Bio-Nano Sector

Published online by Cambridge University Press:  20 July 2012

Elicia Maine
Affiliation:
Beedie School of Business, Simon Fraser University, Vancouver, B.C., Canada
Martin Bliemel
Affiliation:
Australian School of Business, University of New South Wales, Sydney, N.S.W., Australia
Armstrong Murira
Affiliation:
Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, B.C., Canada
James Utterback
Affiliation:
Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA, USA
Get access

Astract

As scientists are able to understand and manipulate ever smaller scales of matter, research in the fields of biotechnology and nanotechnology has converged to enable such radical innovations as lab-on-a-chip devices, targeted drug delivery, and other forms of minimally invasive therapy and diagnostics. This paper provides a descriptive overview of the emerging bio-nano sector, identifying what types of firms are entering, from what knowledge base, where they are located, and their strategic choices in terms of technological diversity and R&D strategy. The firms engaged in bio-nano research and development span the range from start-up firm to multinational pharmaceutical, biotech, chemical, and electronics firms: two thirds of bio-nano firms are relatively young and relatively small. The United States dominates this sector, with more than half of all bio-nano firms located in the USA. Even within this sector which epitomizes the convergence of technology, there is a broad range of technological diversity, with the most diverse firms overall coming from a base in electronics, the most diverse start-up firms coming from a base in nanomaterials, and the most narrowly focused firms coming from a biotechnology/pharmaceutical base. We find that hybridization has been the dominant knowledge diversity strategy, with 93% of the bio-nano firms with nano-patents holding multiclass patents.

Information

Type
Articles
Copyright
Copyright © Materials Research Society 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable